TrialPath

Find a study

Match me to a study

72 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicMental healthLungs & breathingHeart & circulationKidney

62 studies on the map

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) — 89bio Clinical Study Site, BirminghamA Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH — GSK Investigational Site, ArcadiaA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH — 89bio Clinical Study Site, BirminghamA Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH — Akero Clinical Study Site, BirminghamLIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis — The Institute for Liver Health II DBA Arizona Clinical Trials, PeoriaA Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition — Arizona Liver Health, ChandlerA Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis — Akero Clinical Study Site, BirminghamA Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH — GSK Investigational Site, ArcadiaLIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis — University of Alabama at Birmingham, BirminghamA Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) — Arizona Liver Health, ChandlerA Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH — Arizona Liver Health - Chandler, ChandlerA Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH) — Arizona Liver Health - Chandler, ChandlerFibrosis Lessens After Metabolic Surgery — Banner Health Center, PhoenixStudy to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH — University of California San Diego, La JollaDiet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease — Weill Cornell Medicine, New YorkNon-Invasive Quantification of Liver Health in NASH (N-QUAN) — Arizona Liver Health, ChandlerVertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis — University of San Fransisco, San FranciscoEvaluation of Non-Invasive Tests for Metabolic Liver Disease — Clinical Pharmacology of Miami, MiamiA Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) — Arizona Liver Health, ChandlerA Study of Efimosfermin Alfa in Adults With Hepatic Impairment — GSK Investigational Site, RialtoEffect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial — Brigham and Women's Hospital, BostonEndoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease — Brigham and Women's Hospital, BostonQuantifying Hepatic Mitochondrial Fluxes in Humans — Texas Diabetes Institute - University Health System, San AntonioEndoscopic Ultrasound Shear Wave Elastography Study — Brigham and Women's Hospital, BostonAndrogens and NAFLD Longitudinal Cohort Study — University of California San Francisco, San FranciscoReversal of Lipid-Induced Insulin Resistance — Magnetic Resonance Research Center (MRRC), New HavenPredicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis — Mayo Clinic in Rochester, RochesterDigoxin In NASH (CODIN) — Yale New Haven Health, New HavenImpact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD) — Cincinnati Children's Hospital Medical Center, CincinnatiTime-restricted Eating and Healthy Eating in Patients With Metabolic Liver Disease or Cancer — University of California San Diego, La JollaInvestigating the Link Between Type 2 Immunity and NAFLD in Human Obesity — Mayo Clinic in Arizona, ScottsdaleIntermittent Fasting for NAFLD in Adults — Massachusetts General Hospital, BostonPathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) — Yale New Haven Hospital, New HavenEarly Tracking of Childhood Health Determinants (ETCHED) Study — NIDDK, Phoenix, PhoenixRoutine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD) — University of Missouri-Columbia, ColumbiaHarnessing Macrophage Lysosomal Lipid Metabolism in Obesity — University of Missouri School of Medicine, ColumbiaHarnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM) — University of Missouri School of Medicine, ColumbiaBlood Collection Biorepository for Liver Disease Research — University at Buffalo, Buffalo General Medical Center, BuffaloEffect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study) — Univeristy of Colorado Anschutz Medical Campus, AuroraLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance — Stanford University, StanfordHuman Models of Selective Insulin Resistance: Alpelisib, Part I — Columbia University Irving Medical Center, New YorkEffect of Insulin Lowering on Lipogenesis — Columbia University Irving Medical Center, New YorkLow-Dose Pioglitazone in Patients With NASH (AIM 2) — University of Florida, GainesvilleNASH AMPK Exercise Dosing (AMPED) Trial — Penn State Hershey Medical Center, HersheyEvaluating the Pharmacokinetics and Safety of Miricorilant — Site# 433, San AntonioDevelopment of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis — University of Washington, SeattleRandomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant — Virginia Commonwealth University, RichmondMechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease — Ann & Robert H Lurie Children's Hospital of Chicago, ChicagoInAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer — Dana Farber Cancer Institute, BostonThyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans — Harry S. Truman Memorial, Columbia, MO, ColumbiaEffects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease — Henry Ford Health System, DetroitEstrogen Administration for the Treatment of NASH in Postmenopausal Women — Massachusetts General Hospital, BostonEvaluation of Miricorilant on Liver Fat in Patients With MASLD — University of Missouri, ColumbiaThermoacoustic Method for Estimating Liver Fat Fraction — ENDRA Life Sciences, Ann ArborThe Olmsted NAFLD Epidemiology Study (TONES) — Mayo Clinic in Rochester, RochesterRezdiffra Pregnancy and Lactation Registry — Madrigal Pharmaceuticals, West ConshohockenAccurate Point of Care Liver Disease Diagnostics (Phase 2) — University of California San Diego, La JollaBicalutamide Therapy in Young Women With NAFLD and PCOS — University of California San Francisco, San FranciscoAdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL) — AdventHealth Translational Research Institute, OrlandoMilk Thistle Clinical Trial in Pediatric NAFLD — University Hospitals Cleveland Medical Center, ClevelandNon-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES) — National Institutes of Health Clinical Center, BethesdaNAFLD Clinical Care Pathway — Michael E. DeBakey VA Medical Center, Houston, TX, Houston